5-[2-((S)-1-Phenyl-ethylamino)-pyrimidin-4-yl]-6-(3-trifluoromethyl-phenyl)-pyridazin-3-ol | 344465-97-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-[2-((S)-1-Phenyl-ethylamino)-pyrimidin-4-yl]-6-(3-trifluoromethyl-phenyl)-pyridazin-3-ol
• 英文别名: (s)-5-[2-(1-Phenylethylamino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)-pyridazin-3-ol；4-[2-[[(1S)-1-phenylethyl]amino]pyrimidin-4-yl]-3-[3-(trifluoromethyl)phenyl]-1H-pyridazin-6-one
• CAS: 344465-97-0
• 化学式: C₂₃H₁₈F₃N₅O
• 分子量: 437.424
• InChiKey: NEPXZDIDQODLRI-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-[2-((S)-1-Phenyl-ethylamino)-pyrimidin-4-yl]-6-(3-trifluoromethyl-phenyl)-pyridazin-3-ol 在 三氯氧磷 作用下， 反应 24.0h， 以83%的产率得到(s)-6-Chloro-4-[2-(1-phenylethylamino)pyrimidin-4-yl]-3-(3-trifluoromethyl-phenyl)pyridazine
  参考文献：
  名称：

  Pyridazine based inhibitors of p38 MAPK

  摘要：

  Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group alpha and a heteroaryl group beta relative to the nitrogen atom in the 2-position of the central pyridazine. Additionally, substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00834-4
• 作为产物：
  描述：

  3-(2-Methylsulfanyl-pyrimidin-4-yl)-4-oxo-4-(3-trifluoromethyl-phenyl)-butyric acid methyl ester 在 盐酸 、 sodium tungstate 、 双氧水 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 肼 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 乙酸乙酯 、 乙腈 为溶剂， 反应 104.0h， 生成 5-[2-((S)-1-Phenyl-ethylamino)-pyrimidin-4-yl]-6-(3-trifluoromethyl-phenyl)-pyridazin-3-ol
  参考文献：
  名称：

  Pyridazine based inhibitors of p38 MAPK

  摘要：

  Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group alpha and a heteroaryl group beta relative to the nitrogen atom in the 2-position of the central pyridazine. Additionally, substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00834-4

文献信息

• Substituted pyridazines having cytokine inhibitory activity
  申请人：Merck & Co., Inc.

  公开号：US06602872B1

  公开（公告）日：2003-08-05

  There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.

  公开了式(I)的化合物及其药学上可接受的盐，这些化合物对于治疗细胞因子介导的疾病如关节炎具有实用性。
• US6602872B1
  申请人：——

  公开号：US6602872B1

  公开（公告）日：2003-08-05
• Pyridazine based inhibitors of p38 MAPK
  作者：Charles J McIntyre、Gerald S Ponticello、Nigel J Liverton、Stephen J O’Keefe、Edward A O’Neill、Margaret Pang、Cheryl D Schwartz、David A Claremon

  DOI：10.1016/s0960-894x(01)00834-4

  日期：2002.2

  Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group alpha and a heteroaryl group beta relative to the nitrogen atom in the 2-position of the central pyridazine. Additionally, substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity. (C) 2002 Elsevier Science Ltd. All rights reserved.